Safety of mycophenolate in covid-19 infection: A case series
Article Type : Case Report
Author Details:
Volume : 4
Issue : 2
Online ISSN : XXXX
Print ISSN : XXXX
Article First Page : 53
Article End Page : 58
Abstract
Background: The pandemic of Covid-19 infection has affected all countries in the world. Kidney transplant recipients show higher mortality due to Covid-19 infection than general population. Cytokine storm is an important cause of mortality. Antiviral and immunosuppressive agents are used in the treatment of Covid-19 infection. In patients who are on Mycophenolate for other indications, it is promptly discontinued after development of Covid-19 infection. We studied a series of 14 patients in whom Mycophenolate was continued during Covid-19 infection.
Aim: To see whether Mycophenolate administration was safe in Covid-19 infection.
Materials and Methods: We studied records of 14 cases, 7 kidney transplant recipients and 7 patients with glomerular diseases, in whom Mycophenolate was continued along with standard of care during Covid-19 infection.
Results: 4 renal transplant recipients had 30% to 75% lung involvement on high resolution tomography of the chest while 3 patients with glomerular diseases had 30% (1 patient) and 50% (2 patients) lung involvement because of Covid-19 infection. All patients recovered completely within 2 weeks. There was no worsening of renal function and drop in blood cell counts. Mycophenolate was well tolerated, and no adverse effects were noted.
Conclusions: Mycophenolate administration is safe during Covid-19 infection. Mycophenolate, an Inosine Monophosphate Dehydrogenase (IMPDH) inhibitor, decreases guanosine synthesis, the basis of its antiviral and immunosuppressive effects. It could be an effective immunosuppressive agent in Covid-19 infection. Its antiviral effects would be helpful in decreasing the mortality. It is likely to be useful in different strains other viral pandemics in future.
Keywords: Covid-19, Cytokine storm, Mortality, Mycophenolate.
Doi No:-10.18231